Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment
10/6 02:48
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Supplemental Biologics License Application or sBLA for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosin...